Immunoassay Market: Market Size & Forecast 2026

Immunoassays are analytical techniques that use the binding properties of antibodies to detect and quantify specific proteins, hormones, drugs, and infectious disease markers in biological samples. The technology underpins a wide range of clinical applications, from routine cholesterol and thyroid testing to specialized oncology and infectious disease diagnostics. The market spans consumables such as reagents and kits, instruments including analyzers, and associated software platforms used in clinical chemistry, immunology, and hematology laboratories globally.

• •Market valued at approximately $34.48 billion in 2025 with forecasts extending to 2029-2035
• •Products include reagents and kits, instruments, and analyzers across multiple diagnostic settings
• •Core technologies encompass radioimmunoassay, ELISA, chemiluminescence immunoassay, and fluorescence immunoassay

The rising global burden of chronic diseases, including cancer, diabetes, and cardiovascular disorders, is increasing demand for routine and specialized immunoassay testing in hospitals and clinical laboratories. Aging demographics in developed and emerging economies are further amplifying diagnostic testing volumes across a broad spectrum of clinical indications. The COVID-19 pandemic underscored the critical role of immunoassay-based rapid testing and is expected to have lasting effects on infectious disease surveillance infrastructure and preparedness investments.

• •Growing prevalence of chronic and infectious diseases driving higher testing volumes
• •Aging global population increasing demand for routine diagnostic screening
• •Expansion of personalized medicine and companion diagnostics requiring precise immunoassay platforms

The market is segmented by product into instruments, analyzers, and consumables including reagents and kits, with consumables typically representing the largest revenue share due to recurring demand. Technology segmentation includes radioimmunoassay, enzyme immunoassay, chemiluminescent immunoassay, and fluorescent immunoassay, with chemiluminescent platforms gaining prominence for high-throughput clinical applications. Geographically, North America leads the market due to advanced healthcare infrastructure and high diagnostic spending, while the Asia-Pacific region is expected to register the fastest growth rate driven by expanding healthcare access and rising disposable incomes.

• •North America holds the largest market share, supported by advanced laboratory infrastructure
• •Asia-Pacific is the fastest-growing region, fueled by healthcare access expansion and rising disease burden
• •Consumables, particularly reagents and kits, represent the dominant product segment by revenue

What are the recent trends and outlook?

Artificial intelligence and machine learning are increasingly being integrated into immunoassay platforms for enhanced data interpretation, quality control, and predictive diagnostics capabilities. Miniaturization and microfluidic technologies are enabling more compact, efficient, and cost-effective assay systems suitable for decentralized and point-of-care testing environments. The convergence of lab-on-a-chip technologies, connectivity-driven workflow management, and expanded assay menus is expected to sustain market momentum through the forecast period, with the total addressable market projected to expand significantly by the early 2030s.

• •AI and machine learning integration improving assay accuracy, data analysis, and diagnostic decision support
• •Point-of-care and decentralized testing gaining traction through miniaturized and portable immunoassay platforms
• •Lab-on-a-chip and microfluidic innovations driving next-generation assay development with reduced sample volumes